apceth's vision is to improve patients’ lives with next generation cell therapies. Our programs aim to bring transformative and curative drugs to the patients.
apceth-201 are genetically modified MSCs which expresses Alpha-1 Antitrypsin for the treatment of GvHD, IBD, COPD and diabetes.
apceth-301 are MSCs that expresses a cocktail of cytokines which locally activates the immune system to eradicate tumor cells. apceth-301 is being developed for solid tumors.
We are also a leader in GMP manufacturing of cell-based therapies offering cutting-edge expertise and capabilities. Our unique and comprehensive quality management system has allowed us to successfully obtained manufacturing licenses for multiple cell therapy products. Our facilities are located in Munich, Germany.